PD-1/PD-L1 Blockade in the Treatment of Nasopharyngeal Carcinoma

Programmed cell death-1(PD-1)/Programmed cell death ligand-1 (PD-L1) immune check blockade is one remarkable advance in cancer immunotherapy treatment. Clinical trials studying the efficacy of PD-1 blockade alone or combination with other therapy in different types of cancer have been evaluated or are under observation. Nasopharyngeal carcinoma, also called Cantonese cancer, occurs rarely in the western countries but is common in the tumors of head and neck in the South China. NPC is one type of head and neck tumors, but it is quite distinct among the head and neck tumors. Here, we would like to summarize the progress of PD-1/PD-L1 blockade in the treatment of nasopharyngeal carcinoma.